Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year
AbbVie has another blockbuster business emerging.
AbbVie, once renowned for its immunology-focused portfolio, has now expanded into the neuroscience sector, marking a significant shift in its business strategy. The company's neuroscience portfolio is on track to generate approximately $12.7 billion in revenue by 2026, a figure representing a $100 million increase from its guidance following a robust first half of the year.
This projected growth rate remains impressive considering the neuroscience segment generated $10.8 billion in revenue last year and continues to expand at a double-digit pace.
Unlike many pharmaceutical franchises reliant on a single blockbuster drug, AbbVie's neuroscience business has become increasingly diversified. During the second quarter alone, the revenue from the sector climbed by 20.3% year over year, reaching $3.23 billion. Key contributors to this surge include Vraylar, a drug treating schizophrenia and bipolar disorder, which brought in $1.07 billion.
Therapeutic Botox contributed $1.04 billion, while migraine medications Ubrelvy and Qulipta combined for $742 million in quarterly sales. Additionally, Vyalev, a therapy for Parkinson's disease, added another $256 million to the portfolio.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
